WFDC2 and pancreatic neoplasm: Between 1999 and 2005, only 17% of patients with esophageal cancer, 26% of patients with gastric cancer, and 6% of patients with pancreatic cancer survived 5 years after the disease was identified.36 In a gastric study on HE4, they found that HE4 was not secreted in normal gastric mucosa but expressed in mucosa and gastric cancer with intestinal metaplasia.16 According to another study related to HE4 and gastric cancer, HE4 expression was found to be associated with disease stage, prognosis, tumor size, and survival.37